Dr. Schatzman has been Alder's President and CEO since its founding in January, 2004. Prior to co-founding Alder, he was Senior Vice President of Discovery Research at Celltech R&D Inc., where he led a group of 95 scientists responsible for much of the therapeutic antibody pipeline for Celltech. Before Celltech, he was Director of Gene Discovery at Mercator Genetics helping to solve the gene responsible for hereditary hemochromatosis and advancing the Del-1 angiogenesis factor into preclinical models and partnering Del-1 with Valentis. Prior to Mercator, he was at Syntex/Roche Bioscience where he helped found the Cancer and Developmental Biology Institute and served as Preclinical Team Leader for Cytovene and Team Leader for Valcyte, and was responsible for preclinical studies on Cellcept. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco.